

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Geoffrey Brooke
Date of last notice	24 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary
Date of change	26 March 2026
No. of securities held prior to change	1. 22,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan. 1,554,039 fully paid ordinary shares 275,331 unlisted options ex @ \$0.0375 exp 11/9/2026 501,689 listed options ex @ \$0.05 exp 31/5/2027 2. 4,468,033 fully paid ordinary shares. 237,029 unlisted options ex @ \$0.0375 exp 11/9/2026 87,543 listed options ex @ \$0.05 exp 31/5/2027 1,250,001 listed options ex @ \$0.05 exp 30/9/2027
Class	Fully paid ordinary shares
Number acquired	2. 1,357,857 fully paid ordinary shares
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$57,029,99
No. of securities held after change	<ol style="list-style-type: none"> 1. 22,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan. 1,554,039 fully paid ordinary shares 275,331 unlisted options ex @ \$0.0375 exp 11/9/2026 501,689 unlisted options ex @ \$0.05 exp 31/5/2027 2. 5,825,890 fully paid ordinary shares. 237,029 unlisted options ex @ \$0.0375 exp 11/9/2026 87,543 unlisted options ex @ \$0.05 exp 31/5/2027 1,250,001 listed options ex @ \$0.05 exp 30/9/2027
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director Placement Shares following shareholder approval on 18 March 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Steven Gourlay
Date of last notice	24 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. SG Gourlay Nominees Pty Ltd <SG Gourlay Family A/C> - Director of trustee and beneficiary of trust
Date of change	26 March 2026
No. of securities held prior to change	1. 89,362,300 fully paid ordinary shares issued pursuant to Employee Share Plan. 41,003,941 fully paid ordinary shares. 702,864 unlisted options ex @ \$0.0375 exp 11/9/2026 1,757,440 listed options ex @ \$0.05 exp 31/5/2027 25,000,000 listed options ex \$0.05 exp 30/9/2027 2. 20,561,907 fully paid ordinary shares. 1,739,783 unlisted options ex @ \$0.0375 exp 11/9/2026 642,560 listed options ex @ \$0.05 exp 31/5/2027
Class	Fully paid ordinary shares
Number acquired	1. 11,904,762 fully paid ordinary shares
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$500,000.00
No. of securities held after change	<ol style="list-style-type: none"> 89,362,300 fully paid ordinary shares issued pursuant to Employee Share Plan. 52,908,703 fully paid ordinary shares. 702,864 unlisted options ex @ \$0.0375 exp 11/9/2026 1,757,440 listed options ex @ \$0.05 exp 31/5/2027 25,000,000 listed options ex \$0.05 exp 30/9/2027 20,561,907 fully paid ordinary shares. 1,739,783 unlisted options ex @ \$0.0375 exp 11/9/2026 642,560 listed options ex @ \$0.05 exp 31/5/2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director Placement Shares following shareholder approval on 18 March 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr George Morstyn
Date of last notice	24 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. HSBC Custody Nominees (Australia) Limited <A/C 2> - beneficiary
Date of change	26 March 2026
No. of securities held prior to change	1. 2,843,289 fully paid ordinary shares 7,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan. 299,805 unlisted options ex @ \$0.0375 exp 11/9/2026 260,728 listed options ex @ \$0.05 exp 31/5/2027 2. 5,298,174 fully paid ordinary shares. 307,269 unlisted options ex @ \$0.0375 exp 11/9/2026. 113,485 listed options ex @ \$0.05 exp 31/5/2027 1,250,001 listed options ex @ \$0.05 exp 30/9/2027
Class	Fully paid ordinary shares
Number acquired	1. 1,821,991 fully paid ordinary shares
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$76,523.62
No. of securities held after change	<ol style="list-style-type: none"> 4,665,280 fully paid ordinary shares 7,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan. 299,805 unlisted options ex @ \$0.0375 exp 11/9/2026 260,728 listed options ex @ \$0.05 exp 31/5/2027 5,298,174 fully paid ordinary shares. 307,269 unlisted options ex @ \$0.0375 exp 11/9/2026. 113,485 listed options ex @ \$0.05 exp 31/5/2027 1,250,001 listed options ex @ \$0.05 exp 30/9/2027
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Director Placement Shares following shareholder approval on 18 March 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Malcolm McComas
Date of last notice	24 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Direct 2. Indirect 3. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	2. Bunyula Super Pty Ltd <Bunyula Super Fund A/C> - director related entity and contingent beneficial interest 3. McComas Capital Pty Ltd <McComas Family A/C> - controller of trustee & a beneficiary of the trust 4. Speech Dynamics Pty Ltd – director related entity
Date of change	26 March 2026
No. of securities held prior to change	1. 6,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan 300,000 fully paid ordinary shares 150,000 listed options ex @ \$0.05 exp 31/5/2027 2. 1,070,219 fully paid ordinary shares 90,554 unlisted options ex @ \$0.0375 exp 11/9/2026 33,445 listed options ex @ \$0.05 exp 31/5/2027 3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan 301,617 fully paid ordinary shares 110,133 unlisted options ex @ \$0.0375 exp 11/9/2026 40,676 listed options ex @ \$0.05 exp 31/5/2027 4. 1,000,000 fully paid ordinary shares 750,000 listed options ex \$0.05 exp 30/9/2027
Class	Fully paid ordinary shares
Number acquired	4. 714,286 fully paid ordinary shares
Number disposed	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$30,000.01
No. of securities held after change	<ol style="list-style-type: none"> 1. 6,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan 300,000 fully paid ordinary shares 150,000 listed options ex @ \$0.05 exp 31/5/2027 2. 1,070,219 fully paid ordinary shares 90,554 unlisted options ex @ \$0.0375 exp 11/9/2026 33,445 unlisted options ex @ \$0.05 exp 31/5/2027 3. 1,000,000 fully paid ordinary shares issued pursuant to Employee Share Plan 301,617 fully paid ordinary shares 110,133 unlisted options ex @ \$0.0375 exp 11/9/2026 40,676 listed options ex @ \$0.05 exp 31/5/2027 4. 1,714,286 fully paid ordinary shares 750,000 listed options ex \$0.05 exp 30/9/2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director Placement Shares following shareholder approval on 18 March 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Actinogen Medical Limited
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Nicki Vasquez
Date of last notice	24 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	26 March 2026
No. of securities held prior to change	7,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan 366,667 fully paid ordinary shares 183,334 listed options ex @ \$0.05 exp 31/5/2027
Class	Fully paid ordinary shares
Number acquired	82,057 fully paid ordinary shares
Number disposed	-
Value/Consideration includes brokerage/gst <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$3,446.39

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	7,500,000 fully paid ordinary shares issued pursuant to Employee Share Plan 448,724 fully paid ordinary shares 183,334 listed options ex @ \$0.05 exp 31/5/2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Director Placement Shares following shareholder approval on 18 March 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.